miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer

IntroductionERBB3, one of the four members of the ErbB family of receptor tyrosine kinases, plays an important role in breast cancer etiology and progression. In the present study, we aimed to identify novel miRNAs that can potentially target ERBB3 and their biological functions.MethodThe expression levels of miR-143/145 and target mRNA were examined by relative quantification RT-PCR, and the expression levels of target protein were detected by Western blot. We used bioinformatic analyses to search for miRNAs that can potentially target ERBB3. Luciferase reporter plasmids were constructed to confirm direct targeting. Furthermore, the biological consequences of the targeting of ERBB3 by miR-143/145 were examined by cell proliferation and invasion assays in vitro and by the mouse xenograft tumor model in vivo.ResultsWe identified an inverse correlation between miR-143/145 levels and ERBB3 protein levels, but not between miR-143/145 levels and ERBB3 mRNA levels, in breast cancer tissue samples. We identified specific targeting sites for miR-143 and miR-145 (miR-143/145) in the 3’-untranslated region (3’-UTR) of the ERBB3 gene and regulate ERBB3 expression. We demonstrated that the repression of ERBB3 by miR-143/145 suppressed the proliferation and invasion of breast cancer cells, and that miR-143/145 showed an anti-tumor effect by negatively regulating ERBB3 in the xenograft mouse model. Interestingly, miR-143 and miR-145 showed a cooperative repression of ERBB3 expression and cell proliferation and invasion in breast cancer cells, such that the effects of the two miRNAs were greater than with either miR-143 or miR-145 alone.ConclusionTaken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea that different miRNAs in a cluster can synergistically repress a given target mRNA.

[1]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[2]  W. Cho MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. , 2010, The international journal of biochemistry & cell biology.

[3]  K. Nephew,et al.  EGFR signaling in breast cancer: bad to the bone. , 2010, Seminars in cell & developmental biology.

[4]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[5]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[6]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[7]  L. Anderson,et al.  The ERBB3 receptor in cancer and cancer gene therapy , 2008, Cancer Gene Therapy.

[8]  W. Cho,et al.  Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. , 2009, European journal of cancer.

[9]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[10]  J. Segall,et al.  ErbB3-dependent motility and intravasation in breast cancer metastasis. , 2006, Cancer research.

[11]  Ravi Jain,et al.  MicroRNA-143 Regulates Adipocyte Differentiation* , 2004, Journal of Biological Chemistry.

[12]  Jing Li,et al.  miR-145 inhibits breast cancer cell growth through RTKN. , 2009, International journal of oncology.

[13]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[14]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[15]  D. Wheeler,et al.  Mechanisms of resistance to HER family targeting antibodies. , 2010, Experimental cell research.

[16]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[17]  D. Stern ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[18]  X. Chen,et al.  Role of miR-143 targeting KRAS in colorectal tumorigenesis , 2009, Oncogene.

[19]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[20]  N. Wu,et al.  MicroRNA-145 Function as a Cell Growth Repressor by Directly Targeting c-Myc in Human Ovarian Cancer , 2014, Technology in cancer research & treatment.

[21]  N. Guo,et al.  MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. , 2009, Cancer treatment reviews.

[22]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[23]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[24]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[25]  A. Hamburger The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies , 2008, Journal of Mammary Gland Biology and Neoplasia.

[26]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[27]  Edith A Perez,et al.  MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. , 2011, Trends in molecular medicine.

[28]  I. Pogribny,et al.  MicroRNA-mediated drug resistance in breast cancer , 2011, Clinical Epigenetics.

[29]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[30]  R. Mancini,et al.  Novel anti‐ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors , 2012, Journal of cellular physiology.

[31]  Y. Mo,et al.  MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. , 2010, Cancer research.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.